Erythema Infectiosum (Fifth Disease)

Erythema infectiosum is a common, generally self-limiting childhood exanthem caused by parvovirus B19, characterized by a biphasic illness with an initial nonspecific febrile prodrome followed ~1 week later by the classic "slapped-cheek" facial rash and a lace-like reticular body rash. [1-2] While benign in most immunocompetent children, it carries significant risk in specific populations including pregnant women, patients with hemoglobinopathies, and immunocompromised individuals. [2-3]

• Prodrome: Low-grade fever, malaise, headache, myalgia, coryza occurring 7–10 days before rash onset (during viremic phase) [1]
• Rash timing: Bilateral "slapped-cheek" erythema appears first, followed 1–4 days later by a lace-like, reticular, erythematous rash on trunk and extremities [1][4]
• Rash recurrence: Evanescent — can wax and wane for weeks, provoked by sunlight, heat, bathing, exercise, or emotional stress [1]
• Joint symptoms: Arthralgias/arthritis more common in adults (especially women), symmetric, involving small joints of hands, wrists, knees [3][5]
• Pruritus: May accompany the rash [4]
• Exposure history: Sick contacts at school/daycare, known community outbreak, household exposure (50% seroconversion risk with household contact vs. 20–50% in classroom) [5]
• Important negatives: Absence of vesicles, oral lesions, conjunctivitis, lymphadenopathy helps distinguish from other exanthems

• Pallor, tachycardia, fatigue → suspect transient aplastic crisis (especially in sickle cell disease, spherocytosis, thalassemia, iron deficiency anemia) [2][6]
• Pregnancy exposure → risk of hydrops fetalis, fetal death (fetal loss 8–17% before 20 weeks) [5][7]
• Petechial/purpuric rash → atypical presentation; must rule out meningococcemia, ITP, leukemia [8]
• Chest pain, dyspnea, signs of heart failure → parvovirus B19 myocarditis, particularly in young children (median age ~32 months); associated with 19.7% mortality/transplant/LVAD rate during the 2024 outbreak [9-10]
• Neurological symptoms (seizures, encephalitis, ataxia) → reported in 17.8% of hospitalized children during the 2024 outbreak [10]
• Immunocompromised patient with persistent anemia → chronic pure red cell aplasia [1-2]

• Treatment is supportive in immunocompetent patients [3][11]
• Antipyretics/analgesics: Acetaminophen or ibuprofen for fever and arthralgias
• NSAIDs: Useful for adult arthropathy (symmetric polyarthritis may persist weeks to months)
• IVIG: Indicated for chronic pure red cell aplasia in immunocompromised patients and may be considered in severe myocarditis [3][12]
• RBC transfusion: For transient aplastic crisis with significant anemia [6][13]
• No antiviral therapy is available; no vaccine currently approved [14]
• Antihistamines: May help if pruritus is prominent

• No specific dietary triggers or restrictions
• Encourage adequate hydration, especially during febrile prodrome
• No evidence-based dietary interventions for this condition

• Constitutional: Fever, malaise, fatigue (prodromal)
• Skin: Rash character, distribution, timing relative to fever, pruritus
• MSK: Joint pain/swelling (especially in adults — hands, wrists, knees)
• Heme: Pallor, easy bruising, petechiae
• Cardiac: Chest pain, dyspnea, exercise intolerance, palpitations (myocarditis screen)
• Neuro: Headache, seizures, altered mental status
• OB/GYN: Pregnancy status, gestational age, fetal movement

• Daycare/school outbreak history — parvovirus B19 spreads in epidemic waves, especially late winter/spring [15-16]
• Household contacts with sickle cell disease or other hemoglobinopathies — at risk for concurrent aplastic crisis [6]
• Pregnant household members — critical to identify; the infected child is no longer contagious once the rash appears [5]
• Family history of hemolytic anemias (spherocytosis, G6PD deficiency, sickle cell disease)
• Immunocompromised family members (transplant recipients, HIV, chemotherapy)

• Age: Peak incidence in school-age children (5–15 years) [16]
• Season: Late winter through early spring
• Occupation/exposure: Teachers, daycare workers, healthcare workers
• Hemoglobinopathies: Sickle cell disease, thalassemia, spherocytosis → risk of aplastic crisis [6][13]
• Immunosuppression: HIV, transplant recipients, chemotherapy → chronic infection/pure red cell aplasia [1-2]
• Pregnancy: ~35–40% of reproductive-age women are seronegative and susceptible [5]
• Post-COVID-19 pandemic surge: A significant increase in parvovirus B19 cases was observed in 2023–2024 across Europe and the US, likely due to waning population immunity [10][17]

• Rubella — similar maculopapular rash; distinguished by postauricular/suboccipital lymphadenopathy, Forchheimer spots [1]
• Measles (rubeola) — cephalocaudal spread, Koplik spots, higher fever, cough/coryza/conjunctivitis
• Scarlet fever — sandpaper rash, pharyngitis, strawberry tongue, Pastia lines [4]
• Roseola (HHV-6) — rash appears after fever resolves (vs. fifth disease where rash appears with/after mild fever) [4]
• Drug eruption — temporal relationship to medication
• Kawasaki disease — prolonged fever ≥5 days, conjunctival injection, mucositis, extremity changes, lymphadenopathy [18]
• Meningococcemia — petechial/purpuric rash with toxic appearance (cannot-miss diagnosis) [19]
• Systemic lupus erythematosus — malar rash can mimic slapped cheek; distinguished by systemic features
• Hand-foot-mouth disease — vesicular lesions on palms, soles, oral mucosa

• Hemolytic anemias (sickle cell, spherocytosis, thalassemia) — highest risk for aplastic crisis [6][13]
• Immunodeficiency (congenital or acquired) — risk of chronic infection and pure red cell aplasia [1]
• Prior parvovirus B19 infection — IgG provides lifelong immunity; reinfection is rare [2]
• Pregnancy history and current pregnancy status
• Transplant history — solid organ or bone marrow transplant recipients at risk
• Chronic kidney disease — baseline anemia may worsen

• Vital signs: Low-grade fever (often resolved by time of rash); tachycardia if anemic
• Face: Bilateral, confluent erythema of cheeks with circumoral pallor ("slapped cheek") [1][4]
• Trunk/extremities: Lace-like, reticular, erythematous maculopapular rash; may be evanescent [1]
• Joints: Swelling, tenderness (especially in adults — hands, wrists, knees)
• Skin: Check for petechiae/purpura (atypical variant); rash may be difficult to see in dark skin [1][8]
• Pallor: Suggests significant anemia — check conjunctivae, palms
• Cardiac: Gallop, murmur, hepatomegaly → concern for myocarditis [9]
• Abdomen: Hepatosplenomegaly (aplastic crisis, myocarditis)
• Absent findings: No lymphadenopathy, no oral lesions, no vesicles (helps distinguish from other exanthems)

• Routine cases in immunocompetent children: No labs needed — diagnosis is clinical [11]
• Parvovirus B19 IgM/IgG serology: Confirmatory test of choice; ~90% of patients with erythema infectiosum have detectable IgM at presentation [2]
• CBC with reticulocyte count: Essential if aplastic crisis suspected — look for reticulocyte count <1%, significant drop in hemoglobin from baseline [6]
• Parvovirus B19 PCR (NAAT): Preferred in immunocompromised patients (who may not mount IgM response) and in aplastic crisis [2]
• CMP, LDH, haptoglobin, bilirubin: If hemolysis suspected
• Troponin, BNP/NT-proBNP: If myocarditis suspected [9]
• Pregnancy test: In reproductive-age women with exposure

• Not routinely indicated in classic erythema infectiosum
• Echocardiography: If myocarditis suspected (chest pain, heart failure signs, troponin elevation) — assess LV function [9][20]
• Cardiac MRI: Gold standard for myocarditis diagnosis in stable patients [21]
• Fetal ultrasound with MCA Doppler: In pregnant women with confirmed infection — serial monitoring for hydrops fetalis and fetal anemia for 8–12 weeks after maternal infection [5][16]
• Chest X-ray: If respiratory distress or heart failure suspected

• No validated clinical scoring system specific to erythema infectiosum
• Bone marrow biopsy: Rarely needed; may show giant pronormoblasts (pathognomonic) in aplastic crisis [2]
• Endomyocardial biopsy: Gold standard for parvovirus B19 myocarditis confirmation; shows lymphocytic myocarditis with viral DNA on PCR [9][21]
• Fetal blood sampling (cordocentesis): For suspected severe fetal anemia; allows intrauterine transfusion [7][16]

• Not routinely indicated in uncomplicated erythema infectiosum
• Obtain ECG if: Chest pain, dyspnea, tachycardia out of proportion to fever, signs of heart failure
• Parvovirus B19 myocarditis ECG findings: Sinus tachycardia, nonspecific ST-T wave changes, T-wave inversions (inferior/lateral leads), low QRS voltage, peaked P waves [21-22]
• Danger signs: ST-segment elevation — associated with 100% mortality in one pediatric series; AV block, ventricular tachycardia [20][22]

Erythema infectiosum is a benign, self-limiting illness in the vast majority of immunocompetent children, resolving in 1–2 weeks. [3][7] The disease is biphasic: an initial viremic phase (fever, malaise — patient is contagious) followed ~1 week later by the immune-mediated rash phase (patient is no longer contagious). [1][5]

Key clinical pearls:

• By the time the classic rash appears, the patient is no longer infectious — isolation is not necessary once the rash is present [5]
• Adults more commonly present with arthropathy rather than the classic slapped-cheek rash [5][23]
• The rash may be difficult to appreciate in dark skin [1]
• Atypical presentations include petechial/purpuric rash, "gloves and socks" syndrome, and vesiculopustular eruptions [2][8][24]
• The 2023–2024 post-pandemic surge highlighted myocarditis as a serious complication, particularly in children ≤7 years [9-10]

The following figure illustrates the pathophysiology of parvovirus B19 infection across different host populations — normal subjects, patients with hemolytic anemia (aplastic crisis), and immunocompromised patients (chronic anemia):

Immunocompetent children (classic fifth disease)

• Supportive care only — antipyretics (acetaminophen 15 mg/kg q4–6h or ibuprofen 10 mg/kg q6–8h), hydration, rest [3][11]
• Antihistamines for pruritus if needed
• Reassurance that the rash may recur for weeks with triggers (sun, heat, exercise) [1]

Adult arthropathy

• [3]

Transient aplastic crisis (sickle cell, spherocytosis, etc.):

• RBC transfusion as needed for symptomatic anemia [6][13]
• Droplet isolation from pregnant women and other at-risk patients [6]
• Monitor siblings with hemoglobinopathies for concurrent aplastic crisis [6]

Immunocompromised patients with chronic pure red cell aplasia:

• IVIG (0.4 g/kg/day × 5–10 days or 1 g/kg/day × 2–3 days) [3][11]
• Reduction of immunosuppression if possible

Pregnancy

• Confirm infection with IgM/IgG serology [2]
• Serial fetal ultrasound + MCA Doppler every 1–2 weeks for 8–12 weeks [5][16]
• Referral to maternal-fetal medicine if hydrops or fetal anemia suspected [16]
• Intrauterine transfusion for severe fetal anemia (survival 67–85%) [14]

Myocarditis

• ICU-level care for hemodynamic instability [9]
• Standard heart failure management (inotropes, mechanical circulatory support including ECMO if needed) [20]
• IVIG and immunomodulatory therapy considered in select cases [12][21]

Discharge criteria (majority of cases)

• Immunocompetent child or adult with classic presentation
• Well-appearing, hemodynamically stable
• No underlying hemoglobinopathy or immunodeficiency
• Adequate oral intake

Admission criteria

• Aplastic crisis with significant anemia requiring transfusion [6]
• Myocarditis — any signs of cardiac dysfunction (ICU admission in 71% of myocarditis cases during 2024 outbreak) [10]
• Severe anemia with hemodynamic compromise
• Neurological complications (encephalitis, seizures) [10]
• Diagnostic uncertainty with petechial rash requiring workup to exclude meningococcemia or leukemia [8]

Specialist consultation triggers

• Hematology: Aplastic crisis, chronic red cell aplasia
• Maternal-fetal medicine: Confirmed infection in pregnancy [16]
• Cardiology: Suspected myocarditis [9]
• Infectious disease: Immunocompromised patients with persistent infection

Follow-up timing

• Routine cases: No specific follow-up needed unless symptoms persist >4 weeks
• Arthropathy in adults: PCP follow-up in 2–4 weeks if joint symptoms persist
• Pregnancy: Serial ultrasound/Doppler monitoring for 8–12 weeks post-infection [5][16]
• Post-aplastic crisis: Hematology follow-up with repeat CBC/reticulocyte count

Return precautions — advise return for

• New-onset pallor, fatigue, dizziness (worsening anemia)
• Chest pain, difficulty breathing, rapid heartbeat (myocarditis)
• Petechiae, purpura, or bleeding (thrombocytopenia)
• High fever, toxic appearance, neck stiffness
• Persistent or worsening joint swelling >6 weeks

Patient counseling

• The rash is not contagious once it appears — child may return to school/daycare [5]
• Rash may recur intermittently for weeks with sun, heat, or exercise — this is normal and does not indicate reinfection [1]
• Pregnant contacts should be informed and may need serologic testing [5]
• Lifelong immunity develops after infection [2]
• Expected recovery: 1–3 weeks for most cases; arthropathy may take longer in adults [23]

1. Parvovirus B19. — Young NS, Brown KE. The New England Journal of Medicine. 2004.

2. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

3. Erythema Infectiosum and Other Parvovirus B19 Infections. — Kirchner JT. American Family Physician. 1994.

4. Common Skin Rashes in Children. — Allmon A, Deane K, Martin KL. American Family Physician. 2015.

5. Practice Bulletin No. 151: Cytomegalovirus, Parvovirus B19, Varicella Zoster, and Toxoplasmosis in Pregnancy. — Committee on Practice Bulletins—Obstetrics Obstetrics and Gynecology. 2015.

6. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report. — Yates AM, Aygun B, Nuss R, Rogers ZR. Pediatrics. 2024.

7. Prenatal Parvovirus B19 Infection. — Kagan KO, Hoopmann M, Geipel A, Sonek J, Enders M. Archives of Gynecology and Obstetrics. 2024.

8. Generalized Petechial Rashes in Children During a Parvovirus B19 Outbreak. — Edmonson MB, Riedesel EL, Williams GP, Demuri GP. Pediatrics. 2010.

9. Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. — Ammirati E, Veronese G, Raimondi F, et al. Circulation. 2026.

10. Severe Presentations and Outcomes in Hospitalized Pediatric Patients With Parvovirus B19 Infection During the 2024 Outbreak: A Multicenter Prospective Study in Italy. — Venturini E, Tamborino AM, Arrichiello G, et al. The Pediatric Infectious Disease Journal. 2025.

11. Clinical Presentations of Parvovirus B19 Infection. — Servey JT, Reamy BV, Hodge J. American Family Physician. 2007.

12. Parvovirus B19-Associated Myocarditis in Children: A Systematic Review of Clinical Features, Management and Outcomes. — Veronese G, Colombo G, Garascia A, et al. European Journal of Clinical Investigation. 2025.

13. Significance of Parvovirus B19 Infection in Childhood - Collection of Demographic Data, Clinical Presentation, Diagnostic Findings and the Impact on Patients With Hemolytic Anemia. — Lawatsch L, Baier M, Milde T, Gruhn B. Diagnostic Microbiology and Infectious Disease. 2026.

14. Parvovirus B19 Infection in Pregnancy - A Review. — Gigi CE, Anumba DOC. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021.

15. Academy Rash. A Probable Epidemic of Erythema Infectiosum ('Fifth Disease'). — Brass C, Elliott LM, Stevens DA. The Journal of the American Medical Association. 1982.

16. Parvovirus B19 in Pregnancy: A Case Review. — Hunter LA, Ayala NK. Journal of Midwifery & Women's Health. 2021.

17. Is Parvovirus B19 Infection Upsurge in 2023-2024 Associated With Adverse Pregnancy Outcome?. — Prasad S, Khalil A, Yinon Y, et al. Ultrasound in Obstetrics & Gynecology : The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2025.

18. The Rash With Maculopapules and Fever in Children. — Muzumdar S, Rothe MJ, Grant-Kels JM. Clinics in Dermatology. 2019.

19. Evaluating the Febrile Patient With a Rash. — McKinnon HD, Howard T. American Family Physician. 2000.

20. Parvovirus B19 Myocarditis in Children: An Observational Study. — Vigneswaran TV, Brown JR, Breuer J, Burch M. Archives of Disease in Childhood. 2016.

21. Parvovirus B19 Myocarditis in Children: A Diagnostic and Therapeutic Approach. — Esmel-Vilomara R, Dolader P, Izquierdo-Blasco J, et al. European Journal of Pediatrics. 2022.

22. Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. — Law YM, Lal AK, Chen S, et al. Circulation. 2021.

23. Acute Parvovirus B19 Infection: Analysis of 46 Patients. — Tomás-Velázquez A, Escribano Á, Rodríguez-Garijo N, et al. Medicina Clinica. 2020.

24. Human Parvovirus B19-Induced Vesiculopustular Skin Eruption. — Naides SJ, Piette W, Veach LA, Argenyi Z. The American Journal of Medicine. 1988.